Products for Research Use Only

Mycophenolate Mofetil-d4

CAT: 0804-HY-B0199S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0199S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mycophenolate Mofetil-d4 is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH) . Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].
CAS Number
1132748-21-0
UNSPSC
12352005
Hazard Statement
H302
Target
Apoptosis; Drug Metabolite; Endogenous Metabolite; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; Others
Field of Research
Cancer
Purity
99.80
Solubility
DMF : ≥ 14mg/mL|DMSO : ≥ 10mg/mL|Ethanol : ≥ 1.4mg/mL
Smiles
CC1=C2C(C(OC2)=O)=C(C(C/C=C(C)/CCC(OC([2H])([2H])C([2H])([2H])N3CCOCC3)=O)=C1OC)O
Molecular Formula
C23H27D4NO7
Molecular Weight
437.52
Precautions
H302
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Simmons WD, et al. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17 (2) :75-92.|[3]Fulton B, et al. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51 (2) :278-298.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported